Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Listen to the latest hemonc news from international experts
The Non-Malignant Channel is supported with funding from Agios (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
AAV gene therapy in hemophilia: progress, challenges and what comes next
This VJHemOnc podcast explores the evolving role of gene therapy in hemophilia, focusing on the challenges of adeno-associated virus (AAV)-based approaches and the development of next-generation strategies.
Radek Kaczmarek, PhD, Indiana University School of Medicine, Indianapolis, IN, discusses the limitations of AAV gene therapy in hemophilia A, including factor VIII engineering, durability, and liver toxicity. He also examines potential malignancy risks associated with AAV integration and the importance of long-term surveillance following treatment. Finally, Dr Kaczmarek discusses emerging non-AAV approaches, including lentiviral gene therapy, targeted gene insertion, and gene editing, and their potential to address some of the limitations of current gene therapy approaches.
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.
